Omipalisib

1086062-66-9

C25H17F2N5O3S

DMSO : 50 mg/mL (98.91 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble)

PI3K/Akt/mTOR; PI3K/Akt/mTOR; Autophagy

Omipalisib (GSK2126458) is a highly selective and potent inhibitor of PI3K with K_is of 0.019 nM/0.13 nM/0.024 nM/0.06 nM and 0.18 nM/0.3 nM for p110alpha/beta/delta/gamma, mTORC1/2, respectively. IC50 & Target: Ki: 0.019 nM (p110alpha), 0.13 nM (p110beta), 0.024 nM (p110delta), 0.06 nM (p110gamma), 0.18 nM (mTORC1), 0.3 nM (mTORC2) In Vitro: Omipalisib (GSK2126458) potently inhibits the activity of common activating mutants of p110alpha (E542K, E545K, and H1047R) found in human cancer with K_i of 8 pM, 8 pM and 9 pM, respectively. Omipalisib causes a significant reduction in the levels of pAkt-S473 with remarkable potency in T47D and BT474 cells with IC₅₀ of 0.41 nM and 0.18 nM, respectively. Furthermore, Omipalisib (GSK2126458) leads to a G1 cell cycle arrest and produces the inhibitory effect on cell proliferation in a large panel of cell lines, including T47D and BT474 breast cancer lines with IC₅₀ of 3 nM and 2.4 nM, respectively^[1]. The combination of Omipalisib or GSK1120212 with Omipalisib enhances cell growth inhibition and decreases S6 ribosomal protein phosphorylation in drug-resistant clones from the A375 BRAF(V600E) and the YUSIT1 BRAF(V600K) melanoma cell lines^[2]. Omipalisib (GSK2126458) potentiates the antiproliferative activity of DDR1-IN-1 in colorectal cancer cell lines^[3]. In Vivo: In a BT474 human tumor xenograft model, Omipalisib (GSK2126458) treatment results in a dose-dependent reduction in pAkt-S473 levels, and exhibits dose-dependent tumor growth inhibition at a low dose of 300 ug/kg. Besides, Omipalisib (GSK2126458) shows low blood clearance and good oral bioavailability in four preclinical species (mouse, rat, dog, and monkey)^[1].